News Stories

The USAGE Campaign, which launched in 2012 as a joint initiative by the NLA, Kowa Pharmaceuticals America and Eli Lilly & Co., recently was honored with finalist designation for two major industry awards, the PRSA National Silver Anvil and the PRSA Big Apple Awards.

Please help us gain insight into the use of plaque information obtained from coronary CTA in managing your patients by participating in “Potential Clinical Applications of Plaque Imaging by CTA: A Survey,”  conducted by Harvey Hecht and Jagat Narula from Mount Sinai Medical Center and Stephan Achenbach from The University of Erlangen. 

The answer sheet to the survey is available at the end of the document.

On January 29, the U.S. FDA approved mipomersen sodium injection as an adjunct to treat LDL-C, Apo B, total cholesterol, and non HDL-C in patients with homozygous familial hypercholesterolemia (HoFH). Mipomersen, known by the brand name Kynamro, will be marketed in the U.S. by Genzyme, a Sanofi company. The mipomersen clearance follows a 9-6 vote in favor of the drug's approval by the FDA's Endocrinologic and Metabolic Drugs Advisory Committee this past October.